GERN
NASDAQGeron Corporation
Price$1.56+0.30 (+23.32%)
2026-05-212026-08-25
News · 26 weeks48+20%
2026-03-012026-08-23
Mix1490d
- Other6(43%)
- SEC Filings3(21%)
- Leadership2(14%)
- Earnings2(14%)
- Insider1(7%)
Latest news
25 items- PRGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase an aggregate of 311,250 shares of common stock to six newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1.53 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee a
- SECSEC Form SCHEDULE 13G filed by Geron CorporationSCHEDULE 13G - GERON CORP (0000886744) (Subject)
- SECGeron Corporation filed SEC Form 8-K: Results of Operations and Financial Condition8-K - GERON CORP (0000886744) (Filer)
- SECSEC Form S-8 filed by Geron CorporationS-8 - GERON CORP (0000886744) (Filer)
- SECSEC Form 10-Q filed by Geron Corporation10-Q - GERON CORP (0000886744) (Filer)
- PRGeron Corporation Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAchieved $57.5 million in RYTELO® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended Q2 2026 with cash, cash equivalents, restricted cash and marketable securities of $327 million Broadened leadership team with the appointment of Chinmaya Rath as Chief Business Officer Company to host conference call and webcast today, August 5, 2026, at 8:00 a.m. ET FOSTER CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceut
- PRGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1.44 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee an
- PRGeron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com. About Geron
- PRRectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive ChairmanThe appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms. CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as
- PRGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron’s new Chief Business Officer, as an inducement material to his acceptance of employment with Geron. The stock option was granted on July 13, 2026. The stock option has an exercise price of $1.42 per share, which is equal to the closing price of Geron’s common stock on the grant date, has a ten-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniver
- PRGeron Announces Appointment of Chinmaya Rath as Chief Business OfficerFOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Chinmaya Rath as Chief Business Officer. "Chinmaya is an experienced business development leader who will bring strategic insights and further executional focus to our team," said Harout Semerjian, President and Chief Executive Officer of Geron. "His appointment underscores our continued dedication to maximizing the value of RYTELO across the globe and evaluating opportunistic innovation to build a leading hematology company." "RYTELO’s best-in-class profile, s
- INSIDERDirector Spiegel Robert J. was granted 6,103 shares, increasing direct ownership by 3% to 205,810 units (SEC Form 4)4 - GERON CORP (0000886744) (Issuer)
- PRGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees as an inducement material to such employees' acceptance of employment with Geron. The stock options have an exercise price of $1.23 per share, which is equal to the closing price of Geron's common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee a
- PRGeron to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceFOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL. A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron's website at www.geron.com. About GeronGeron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our firs
- SECSEC Form 8-K filed by Geron Corporation8-K - GERON CORP (0000886744) (Filer)
- INSIDERSEC Form 4 filed by Director Spiegel Robert J.4 - GERON CORP (0000886744) (Issuer)
- INSIDERSEC Form 4 filed by Director Molineaux Susan4 - GERON CORP (0000886744) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcdonald John F4 - GERON CORP (0000886744) (Issuer)
- INSIDERSEC Form 4 filed by Director O'Farrell Elizabeth G.4 - GERON CORP (0000886744) (Issuer)
- INSIDERSEC Form 4 filed by Director Bir Dawn Carter4 - GERON CORP (0000886744) (Issuer)
- PRCell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun
- PRGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron. The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron's common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and
- PRFirst Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs FOSTER CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Associa
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Geron CorporationSCHEDULE 13G/A - GERON CORP (0000886744) (Subject)
- SECSEC Form 10-Q filed by Geron Corporation10-Q - GERON CORP (0000886744) (Filer)
GERN FAQ
7 questionsWhat does Geron Corporation do?
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Where does GERN stock trade?
Geron Corporation (GERN) is listed on NASDAQ.What sector and industry is GERN in?
Geron Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Geron Corporation go public?
Geron Corporation (GERN) completed its IPO in 1996.What are analysts saying about GERN?
Geron Corporation has had 8 recent analyst actions on file. The most recent action was from Goldman: Sell with a $100.00 price target on 2025-07-10.What companies are similar to GERN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GERN side-by-side with any of them on Quantisnow.How can I track GERN on Quantisnow?
Quantisnow aggregates Geron Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GERN to receive live email and push alerts on every new disclosure.